Global Oral Typhoid Vaccine Market by Vaccine Type (Live Attenuated Oral Typhoid Vaccine, Inactivated Oral Typhoid Vaccine), by End-Use Industry (Hospitals & Clinics, Government Health Programs, Pharmacies & Retail Healthcare); Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Oral Typhoid Vaccine Market was valued at USD 0.4 Billion in 2024-e and will surpass USD 0.7 Billion by 2030; growing at a CAGR of 12.2% during 2025 - 2030.

The Oral Typhoid Vaccine Market is experiencing growth due to the increasing global awareness of typhoid fever and the rising demand for accessible vaccination methods. Typhoid fever, caused by the bacterium Salmonella typhi, remains a significant health issue in many developing countries, where sanitation and clean water access are limited. Oral vaccines, offering a convenient and non-invasive alternative to traditional injectable vaccines, are gaining traction due to their ease of administration and cost-effectiveness. The market is driven by the need to reduce the burden of typhoid fever through vaccination, especially in regions where the disease is endemic, and to provide solutions that are simple for healthcare systems to implement.

Live Attenuated Oral Typhoid Vaccine Segment Is Largest Owing to Efficacy and Long-Term Protection

The live attenuated oral typhoid vaccine segment is the largest in the market, primarily due to its proven efficacy and ability to offer long-term protection against typhoid fever. Live attenuated vaccines are made from weakened forms of the Salmonella typhi bacterium, which stimulates an immune response without causing the disease. This vaccine type has been shown to provide robust protection and has a long shelf life, making it particularly suitable for large-scale vaccination campaigns in endemic regions.

The convenience of the oral form further drives its widespread use, as it eliminates the need for needles and syringes, making it more acceptable and easier to distribute. The availability of oral vaccines is an important factor for increasing vaccination coverage in low-resource settings, contributing to the large share of live attenuated vaccines in the overall market.

Inactivated Oral Typhoid Vaccine Segment Is Fastest Growing Owing to Enhanced Safety and Stability

The inactivated oral typhoid vaccine segment is the fastest growing in the market, driven by its enhanced safety profile and stability. Unlike live attenuated vaccines, inactivated vaccines contain killed bacteria that cannot cause disease, making them a safer option for certain populations, such as individuals with compromised immune systems or those in sensitive age groups. Inactivated vaccines are also more stable under varying environmental conditions, making them easier to store and transport in areas with limited cold chain infrastructure.

The rising demand for safe and reliable vaccination options, particularly in regions with significant typhoid fever outbreaks, is contributing to the rapid growth of the inactivated oral vaccine segment. Additionally, the increasing adoption of these vaccines in global immunization programs is driving their expansion.

Government Health Programs Segment Is Largest End-Use Industry Owing to Public Health Initiatives

The government health programs segment is the largest end-use industry in the oral typhoid vaccine market, driven by large-scale immunization campaigns aimed at controlling typhoid fever. Governments in endemic regions are increasingly implementing public health initiatives to reduce the incidence of typhoid fever and improve overall public health. Oral typhoid vaccines are a key component of these efforts, offering a cost-effective and easy-to-administer solution for mass vaccination programs.

Governments are also partnering with international health organizations to ensure that vaccines reach vulnerable populations in rural or underserved areas. These initiatives contribute significantly to the large share of government health programs in the oral typhoid vaccine market.

Asia Pacific Is Largest Region Owing to High Incidence of Typhoid Fever and Growing Vaccination Efforts

Asia Pacific is the largest region in the oral typhoid vaccine market, primarily due to the high incidence of typhoid fever in the region and ongoing vaccination efforts to control the disease. Countries such as India, Pakistan, and Bangladesh report a significant number of typhoid fever cases annually, making vaccination a critical part of public health initiatives. The availability of oral typhoid vaccines in these regions is helping to address the growing demand for accessible and effective vaccination solutions.

Furthermore, governments and health organizations in the region are increasingly adopting oral typhoid vaccines as part of mass immunization programs to combat the widespread burden of the disease. This has made Asia Pacific the largest regional market for oral typhoid vaccines.

Competitive Landscape and Key Players

The Oral Typhoid Vaccine Market is competitive, with key players such as Sanofi Pasteur, Bharat Biotech, and GlaxoSmithKline leading the development and distribution of oral typhoid vaccines. These companies are at the forefront of vaccine innovation, focusing on improving vaccine safety, efficacy, and accessibility.

The competitive landscape is marked by ongoing research to develop newer, more effective oral typhoid vaccines, along with efforts to expand access in low-income countries. Strategic collaborations with governments and international health organizations, as well as partnerships with healthcare providers, are key strategies employed by leading players to strengthen their position in the market. As the demand for typhoid vaccination continues to grow, companies in the oral typhoid vaccine space are expected to enhance their product offerings and expand distribution networks to meet the needs of global public health initiatives.

Recent Developments:

• Sanofi Pasteur launched an updated oral typhoid vaccine with improved protection and enhanced storage capabilities.
• Bharat Biotech received regulatory approval for its new oral typhoid vaccine designed for mass immunization campaigns in developing countries.
• Merck & Co., Inc. announced a partnership with global health organizations to distribute oral typhoid vaccines to low-income regions.
• Serum Institute of India Pvt. Ltd. introduced a cost-effective oral typhoid vaccine for use in rural healthcare programs.
• Panacea Biotec expanded its oral typhoid vaccine production capacity to meet the rising global demand for vaccination programs.

List of Leading Companies:

• Sanofi Pasteur
• GlaxoSmithKline
• Bharat Biotech
• Bio-Med Pvt. Ltd.
• Serum Institute of India Pvt. Ltd.
• China National Biotec Group
• Panacea Biotec
• Beijing Tiantan Biological Products
• Indian Immunologicals Ltd.
• Merck & Co., Inc.
• EuBiologics Co., Ltd.
• Novartis AG
• The Institute of Vaccines and Sera
• Crucell (Johnson & Johnson)
• JN International Medical Corporation

Report Scope: